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Abstract 
The association between heterocyclic aromatic amine (HCA) intake and prostate cancer 
(PCa) risk may be modified by genetic variation in enzymes involved in HCA metabolism. 
We examined this question in a case-control study nested within the European Prospective 
Investigation into Cancer and Nutrition-Heidelberg cohort. The study included 204 PCa cases 
and 360 matched controls. At baseline, participants provided dietary and lifestyle data and 
blood samples which were used for genotyping. Dietary HCA intake (2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,8-dimethylimidazo [4,5-f]quinoxaline 
(MeIQx), and 2-amino-3,4,8-dimethylimidazo [4,5-f]quinoxaline (DiMeIQx) was estimated 
using information on meat consumption, cooking methods, and browning degree. Risk 
estimates for gene*HCA interactions were calculated by unconditional logistic regression. 
We found inverse associations between PhIP, MeIQx, or DiMeIQx intake and PCa risk when 
having <2 deletions of the GSTT1 and GSTM1 genes (Pinteraction: 0.03, 0.01, and 0.03, 
respectively), which is supported by analysis of darkly browned meat consumption data. 
Statistically significant effect modification of both HCA (DiMeIQx) and darkly browned 
meat intake and PCa risk was observed for allelic variants of MnSOD (rs4880) (Pinteraction: 
0.02). Despite limitations due to study size, we conclude that the association between HCA 
intake and PCa risk could be modified by polymorphisms of GSTT1, GSTM1, and MnSOD.  
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Introduction 
A western diet has long been considered as a potential risk factor for prostate cancer (PCa). 
In the context of meat consumption, evidence is weak for an association between both red 
and processed meat intake and PCa risk 1-2. However, the intake of grilled meat is thought to 
be related to PCa risk since high-temperature cooking of meat leads to formation of 
mutagenic heterocyclic aromatic amines (HCA), which have been shown to induce tumours 
in experimental animal models 3-4. Cooking at higher temperatures and for longer periods of 
time both result in formation of more HCA 3-4. To date, several observational studies have 
evaluated the association of intake of meat cooked at high temperature and PCa risk, but 
results are inconsistent 5-9.  
 
The association between PCa risk and intake of the three most mass-abundant HCAs detected 
in cooked meat, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,8-
dimethylimidazo [4,5-f]quinoxaline (MeIQx), and 2-amino-3,4,8-dimethylimidazo [4,5-
f]quinoxaline (DiMeIQx), was also studied in our European Prospective Investigation into 
Cancer and Nutrition (EPIC)-Heidelberg cohort. Even though meat consumption, cooking 
methods, and degree of browning of the respective food items were assessed with a detailed 
questionnaire, the results did not indicate that HCA intake, as consumed in a regular diet, was 
associated with PCa risk 10-11. However, experimental studies have shown that levels of PhIP 
approximating human dietary exposure stimulate cellular signalling pathways and result in 
increased growth and migration, suggesting a link with the promotion and progression of 
neoplastic disease 4, 12. One of the reasons for our null-findings might be that the association 
between HCA intake and PCa risk is modified by different genotypes/polymorphisms in 
genes encoding for HCA-metabolizing enzymes.  
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So far, only two studies investigated such gene-diet interactions on PCa risk 13-14, but 
evidence has been found for other cancers such as the GST status-diet interaction in the 
context of lung cancer15Therefore, we aimed to assess interactive effects of polymorphisms 
of genes involved in the metabolism of HCA on the association between HCA and PCa risk 
in a case-control study nested within the prospective EPIC-Heidelberg cohort.  
 
Methods 
Study population 
Data was taken from the EPIC-Heidelberg study, an ongoing prospective cohort study 
assessing the association between dietary, lifestyle, and metabolic factors and risk of cancer. 
From 1994 to 1998, a total of 11,928 men aged 50-65 years and 13,612 women aged 35-65 
years were recruited from the general population of Heidelberg and surrounding communities 
16. At baseline, dietary, lifestyle, medical and socioeconomic data were collected via self-
administered questionnaires and personal interviews. The cohort is followed up by mailed 
questionnaires in intervals of about three years to assess information on health status, diet, 
and lifestyle 17. Diet was assessed by using a validated food-frequency questionnaire (FFQ) 
18.  
 
During the second follow-up of the cohort (2002-2004), 11,605 men were contacted; of these, 
9,864 participants completed a 158-item FFQ. This FFQ included detailed questions on meat 
preparation methods and preferred degree of browning. Mean daily dietary intake of HCAs 
from meat was calculated by using published data on the HCA content of different types of 
meat in combination with information on degree of browning, cooking methods, and the 
amount of meat intake 10. Details about the development of this short questionnaire to assess 
the dietary intake of HCA have been published elsewhere 19. 
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Self-reported cases of PCa were verified based on medical reports by the study physician. 
Additionally, death certificates of deceased participants were checked for PCa as underlying 
cause of death. Information on stage and grade of PCa was extracted by the study physician 
from pathology reports, including tumour nodal metastasis (TNM) stage and Gleason 
histologic grade. Advanced PCa was defined as PCa with a Gleason score ≥ 7, a TNM 
staging score of T3/T4, N1-N3, or M1, or PCa as the underlying cause of death.  
 
For the present study, we used a nested case-control approach based on all male EPIC-
Heidelberg participants with blood samples available and free of prevalent cancer (except 
nonmelanoma skin cancer) at baseline. All incident PCa cases (C61, C63.8 and C63.9; 
International Classification of Disease for Oncology, Second Edition) diagnosed by end of 
February 2007 were selected. Following an incidence density sampling protocol, two controls 
were matched per case by age (5-year age groups) and time of recruitment (6-months 
intervals). After excluding those with no information on HCA intake, the final study 
population comprised 203 cases and 360 controls.  
 
All participants gave written informed consent and the study was approved by the ethics 
committee of the Heidelberg Medical School.  
 
Laboratory Analyses 
Genomic DNA was extracted from buffy coat with FlexiGene kit (Qiagen, Hilden, Germany) 
in accordance with the manufacturer’s instructions. DNA was stored at 4°C until use. To 
determine deletions of the GSTM1 and GSTT1 genes, a semi-quantitative genotyping assay 
on the LighCycler 480 (Roche, Mannheim, Germany) was used, with multiplexing of both 
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genes using albumin as reference gene and internal control to confirm amplification 20. This 
method allows for the distinction of homozygous, heterozygous, and non-carriers. 
Determination was done in triplicated and a SD of >10% led to repeated analysis. Five 
percent of the samples were repeated for quality-control reasons and concordance of the 
assigned genotypes was >95%. Genotyping for polymorphisms of the genes NQO1 (C609T, 
rs1800566), GSTA1 (G-52A, rs3957357), GSTP1 (A313G, rs1695; C341T, rs1138272), 
MnSOD (C47T, rs4880), CYP1A1 (3801T>C, rs4646903 [CYP1A1*2A]; C1382A, 
rs1799814 [CYP1A1*4]), GPX1 (C>T, Pro198Leu, rs1050450), and GPX4 (C718T, 
rs713041) were done as multiplex on the MassArray system (Sequenom, San Diego, USA) 
applying the iPLEX method and matrix-assisted laser desorption/ionization – time-of-flight 
mass spectrometry for analyte detection. The analysis was carried out by BioGlobe GmbH 
(Hamburg, Germany). All duplicated samples (quality-control repeats of 8% of the samples) 
to verify inter-experimental reproducibility and accuracy delivered concordant genotype 
results. The genotype could not be assigned to six samples for the GPX1 single nucleotide 
polymorphism (SNP) and to three samples for the GPX4 SNP. All laboratory analyses were 
carried out with the laboratory personnel blinded to the case-control status.  
 
Statistical methods 
Baseline characteristics of the study population are given as mean and SD or percentages by 
case-control status. Median and interquartile range were computed for dietary intake data. 
Genotype frequencies of all studied gene polymorphisms are presented and the χ2 test was 
used to check for Hardy-Weinberg equilibrium. The associations between those 
polymorphisms not previously studied in the context of PCa risk 21-22 were calculated with 
conditional logistic regression estimating odds ratios (OR) and 95% confidence intervals 
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(CI), with the most frequent variant being the reference category. The analysis was stratified 
by case set.  
 
To evaluate potential effect modification of the association between HCA intake and PCa risk 
by genotype, we calculated OR (95%CI) of PCa for each HCA intake variable stratified by 
genotype with unconditional logistic regression adjusting for the matching variables (time of 
recruitment and 5-year age groups) and family history of PCa. Each HCA intake variable was 
also adjusted for daily energy intake (per 1000 kcal). Due to the small units of each HCA 
intake variable, we changed the units of each component as following: PhIP intake was based 
on 50 ng/1000kcal increments, whereas MeIQx intake and DiMeIQx were based on 10 
ng/1000kcal and 1ng/1000kcal increments, respectively. All HCA intake variables were 
analyzed as continuous variables. Because of the small numbers in some genotype categories, 
we also combined the heterozygote and homozygote (mutant) categories. Furthermore, we 
combined GSTM1 and GSTT1 genotypes by counting the number of deleted alleles and 
grouping into zero to one, two, and three to four deleted alleles. We repeated the above 
analysis with additional adjustment for intake of red meat, processed meat, fruit and 
vegetables, and intake of glucosinolates. Statistical significance of the interaction between 
genotypes and HCA intake (cross-product) was assessed with the Wald-test. To verify 
whether other carcinogenic meat compounds (e.g. polycyclic aromatic hydrocarbons (PAH)) 
are involved in addition to HCA we repeated the above analyses for ‘meat intake by degree of 
browning’ (10 g/day increments of dark or light browned consumed meat) which may capture 
both HCA and PAH intake. All analyses were conducted with Statistical Analysis Systems 
(SAS) release 9.1.3 (SAS Institute, Cary, NC).   
 
Results 
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Baseline characteristics of the study population are presented in Table 1. Cases and controls 
did not differ with respect to age or BMI. Cases were less likely to be former or current 
smokers and had less often a university degree. More cases than controls reported a positive 
family history of PCa.  
 
The associations between gene polymorphisms and prostate cancer risk (main effects) were 
reported earlier 21-22 and are thus not shown here. The allele frequencies of the selected 
genetic variants in PCa cases and controls are shown in Table 2. Among the newly tested 
genetic variants GSTP1 (C341T, rs1138272), MnSOD (C47T, rs4880), and CYP1A1 
(3801T>C, rs4646903; C1382A, rs1799814)), the CYP1A1*4 variant rs1799814 was found 
to be statistically significantly associated with PCa risk: men with a CA genotype were more 
likely (OR: 1.94, 95%CI: 1.08-3.48) to develop PCa compared to men with the wildtype.  
As reported earlier, no significant (main) effects of HCAs on PCa risk were found in this 
cohort 11. 
 
Next, we assessed how gene polymorphisms might affect the association between different 
types of HCA intake and PCa risk. From Table 3 it can be seen that there was an inverse 
association between intake of PhIP, MeIQx, or DimeIQx and risk of PCa when having less 
than two deletions of the GSTT1 and GSTM1 genes (Pinteraction: 0.03), though none of the OR 
were found to be statistically significant  (e.g. OR when having <2 deletions for association 
between energy-adjusted PhIP intake (per 50ng/d) and PCa: 0.55 (95%CI: 0.30-1.02)). We 
also identified a statistically significant interaction between MnSOD (rs4880) and DiMeIQx 
intake on PCa risk (Pinteraction: 0.02) such that homozygous carriers of the mutant allele may 
have a lower risk. Additionally, there was a statistically significant association between 
GPX4 (rs713041) and DiMeIQx intake on PCa risk (Pinteraction: 0.03), indicating that the wild 
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type was at increased risk. Adjustment for intake of red meat, processed meat, fruit and 
vegetables, and intake of glucosinolates did not alter the results (results not shown).  
 
Subsequently we tested the same associations and effect modifications for advanced PCa 
(results not shown). We only found a statistically significant effect modification by deletions 
of the GSTT1 and GSTM1 genes for the association between intake of energy-adjusted PhIP 
(per 50 ng/d) and risk of advanced PCa (OR2del: 0.51, 95%CI: 0.22-1.20; OR3-4del: 0.78, 
95%CI: 0.55-1.11; Pinteraction: 0.03). 
 
Finally, we studied how the association between 10 g/day increments of consumption of 
lightly and darkly prepared meat and risk of prostate cancer was modified by different gene 
polymorphisms (Table 4). Using the food-based data we could confirm allelic variants of 
MnSOD (rs4880) as possible effect modifiers (Pinteraction: 0.02) as already identified by means 
of DiMeIQx intake data. A statistically significant inverse association between consumption 
of darkly prepared meat and risk of prostate cancer existed in men with the TT genotype, 
while in men with the wild type or heterozygote form there was no association. In addition, 
we found indication for effect modification by variants of GSTM1 and T1, statistically 
significant for men with no deletions in GSTT1 and consumption of darkly browned meat 
(Pinteraction: 0.07). 
 
Discussion 
In the current study, we examined effect modification of the association between dietary 
intake of the heterocyclic amines PhIP, MeIQx, and DiMeIQx, and PCa risk by 
polymorphisms in genes encoding for HCA-metabolizing enzymes. Our results showed 
inverse associations between intake of PhIP, MeIQx, or DiMeIQx and risk of PCa when 
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having less than two deletions of the GSTT1 and GSTM1 genes. A statistically significant 
interaction was also noted between DiMeIQx intake and the polymorphism rs4880 of the 
MnSOD locus (Pinteraction: 0.02). These results were largely supported by using food-based 
data, i.e. differently prepared meat intake data, instead of HCA intake data. 
 
Observational studies based on dietary questionnaires have found contradicting results for the 
association between meat cooking methods (or HCA intake) and risk of PCa. For instance, 
the NIH-AARP Diet and Health study, containing 10,313 PCa cases, assessed different types 
of meat-cooking methods and found that grilled/barbecued meats were related with an 11% 
risk increase of total PCa and a 36% risk increase of advanced PCa 9. In contrast, the 
Agricultural Health Study, based on 57,311 men, did not find an association between specific 
cooking methods and PCa risk, but intake of well or very well done total meat was associated 
with a 1.26-folded increased PCa risk and a 1.97-fold increased risk of advanced disease 8. In 
the EPIC-Heidelberg cohort, based on 9,578 men, dietary HCA intake was estimated using 
information on meat consumption, cooking methods, and preferred degree of browning, but 
the data also did not support the hypothesis that HCA intake as consumed in a regular diet is 
a risk factor for PCa 11. The current study aimed to explain some of these contradictive 
findings by assessing genetic polymorphism and as a consequence inter-individual 
variability. 
 
To date only two nested case-control studies investigated how risk of prostate cancer 
associated with dietary HCAs intake may be modified by single nucleotide polymorphisms 
(SNP) in genes involved in the HCA metabolism 13-14. In the study based on the Prostate, 
Lung, Colorectal, and Ovarian Cancer Screening Trial they studied 12 different genes 
(CYP1A1, CYP1A2, CYP1B1, GSTA1, GSTM1, GSTM3, GSTP1, NAT1, NAT2, 
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SULT1A1, SULT1A2, and UGT1A locus), whereas the study from the Multiethnic Cohort 
assessed NAT1 and NAT2 acetylator genotypes. The later one did not find evidence for an 
effect-modification by these genotypes 13, but the study by Koutros and colleagues found 
evidence for effect-modification by polymorphisms of the GSTM3 locus 14. Thus, HCA-gene 
interactions have not been studied extensively and need to be addressed in other studies with 
detailed information on HCA intake and SNPs. 
 
Different enzymes are involved in the metabolism of HCA and hence functional 
polymorphisms of their genes may modify the association between HCA and risk of PCa. 
Heterocyclic amines require metabolic activation to exert their genotoxic effects which 
involves phase I hepatic cytochrome P450 (CYP)-mediated N-hydroxylation followed by 
phase II conjugation of the N-hydroxylamines to ester derivatives that may react with DNA 
23-24. N-acetyltransferases (NATs) and sulfotransferase (SULT) can then activate N-hydroxy-
HCA, and more specifically an ATP-dependent pathway of activation has been identified to 
form PhIP in the prostate 23, 25. As a consequence, increased expression and metabolic 
activation of CYP1A1, CYP1A2 and CYP1B1 has been shown in benign prostatic hyperplasia 
(BPH) tissue 23, 26. In contrast, HCA carcinogens are known to be detoxified by gluathione S-
transferases (GSTs) and possibly also NADPH-quinone oxidoreductase (NQO1) 22-23, 25. 
Recently, polymorphisms of mangane superoxide dismutase (MnSOD), an enzyme involved 
in the protection from reactive oxygen species (ROS)-medicated DNA damage, were also 
found to be related with risk of PCa 27. In the context of cellular oxidative stress, glutathione 
peroxidases (GPx) may be another type of enzymes involved in PCa risk as they are 
important components of the redox control system in humans 21.  
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In our EPIC-Heidelberg cohort, we previously have shown that polymorphisms of GSTM1, 
GSTT1, GSTP1, GSTA1, NQO1, GPX1, and GPX4 were not associated with PCa risk 21-22. 
From the additional polymorphisms assessed in this study, the C/A substitution of CYP1A1 
(rs1799814) was the only polymorphism found to increase the risk of PCa considerably. To 
date, only one experimental study compared frequencies of CYP1A1*4 (rs1799814) among 
PCa cases and unaffected men 28, but did not find any statistically significant differences. In 
contrast, the study by Chang and colleagues found an association between polymorphisms of 
CYP1A1*2A and CYP1A1*2C and PCa risk 28. We did not have information on CYP1A1*2C 
in this study, but for CYP1A1*2A we found no association.  
 
We found that in participants with less than two deletions of the GSTT1 and GSTM1 genes, 
higher intake of PhIP, MeIQx, or DiMeIQx was associated with a lower risk of PCa overall 
compared to those with two or more deletions. This reflects the fact that subjects 
homozygous for a null allele are considered detoxification deficient 29 and thus less protected 
for the carcinogenic properties of HCA. In contrast, a lower risk of advanced PCa was found 
when having more than 2 deletions, which may suggest a different mechanism of action 
between HCA, the studied SNPs, and development versus progression of PCa. Given the 
existing literature, it is somewhat surprising to see a decreased risk instead of a less increased 
risk of PCa related to higher HCA intake 30. However, the HCA-based results are confirmed 
to some degree by using meat consumption data. 
 
The association between DiMeIQx intake and PCa risk was modified by a polymorphism of 
MnSOD (C47T). Participants with a homozygote mutant genotype (who have an amino acid 
change from valine (Val) to alanine (Ala)) had a decreased risk of PCa when having a higher 
DiMeIQx intake or a higher intake of darkly prepared meat. Subjects with the Ala/Ala 
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phenotype (i.e., CC coded) may have higher MnSOD activity compared to those with the 
Val/Val or Ala/Val phenotype 31. A recent meta-analysis based on 8,962 subjects showed that 
those with Ala variant genotypes were at increased risk of PCa compared to those with the 
wild type 31, which thus suggests that MnSOD as an endogenous antioxidant in mitochondria 
may play an important role in preventing PCa 31. However, only one study investigated the 
MnSOD genotype in relation to HCA (due to smoking) and PCa risk and showed that there 
was only an association between MnSOD Ala/Ala genotype and PCa risk among rapid NAT1 
genotypes and smokers 27.  
 
A major strength of the present nested case-control study is its prospective design, the high 
follow-up rate (>90%), and the medically confirmed diagnoses of PCa. Furthermore, we were 
able to adjust our analyses with respect to known or suspected confounders, but residual 
confounding cannot be completely ruled out. Our sample size of 203 cases was rather small, 
but we improved study power by matching two controls per case. However, due to missing 
data on HCA some cases only had one control. Although we were able to determine some 
gene-diet interaction effects, we might not have had enough power to detect some 
associations with smaller effects. Moreover, we did not adjust for multiple testing. Thus, 
results have to be seen as a first indication for possibly relevant effect modification that has to 
be confirmed in larger studies, especially given the limited statistical significance of our 
findings. Another limitation of this study is the possible misclassification of HCA intake, 
even though the 2 major determinants (i.e., degree of browning and preparation method) were 
included in the photo-based questionnaire and we previously showed a positive association 
between HCA intake and risk of colorectal adenomas in the same cohort using the same 
dietary questionnaire 32. We also lack data on other possible genotypes that might modify the 
association between HCA intake and PCa risk (e.g. CYP1A1*2C or NAT1/2).  
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Conclusion 
This study indicates that the association between HCA intake and PCa risk – as well as 
consumption of darkly browned meat - is modified by polymorphisms in GSTT1, GSTM1, 
and MnSOD, however, these modifications are not necessarily concordant with the 
underlying biological hypotheses. Considering genetic variation is thus an important step in 
elucidating the mechanism of action between HCA or meat intake and risk of PCa. Other 
larger studies are needed to investigate the complex interplay of polymorphisms in genes 
encoding HCA-metabolizing enzymes and intake of different HCA. 
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Cases (n=203) Controls (n=360)
Mean (SD) Mean (SD)
Age 57.91 (5.0) 57.93 (5.0)
BMI (kg/m2) 27.19 (3.4) 27.23 (3.7)
N (%) N (%)
Education level
No/primary school 69 (34.0) 103 (28.7)
Vocational/other secondary school 69 (34.0) 118 (32.9)
University 65 (32.0) 138 (38.4)
Smoking status
Never 80 (39.4) 123 (34.2)
Former 95 (46.8) 177 (49.2)
Current 28 (13.8) 60 (16.7)
Positive family history of PCa 14 (6.9) 7 (2.0)
Advanced PCa 98 (48.3)
Median (Interquartile range) Median (Interquartile range)
Energy Intake (kcal/d) 1993 (1723-2371) 2076 (1732-2558)
HCA Intake (ng/day)
Total PhIP 27.1 (11.4-79.1) 32.9 (12.0-86.2)
Total MeIQx 16.2 (8.0-34.1) 18.0 (8.0-37.3)
Total DiMeIQx 1.8 (0.8-4.2) 2.2 (0.8-4.5)
Total PhIP 13.1 (6.0-37.1) 15.8 (6.0-40.3)
Total MeIQx 7.8 (4.0-16.2) 8.5 (4.1-16.8)
Total DiMeIQx 0.9 (0.4-2.0) 1.1 (0.4-2.3)
Very light/light 22.7 (9.9-37.4) 23.7 (9.8-44.2)
Energy adjusted HCA Intake (ng/1000 kcal)
Meat intake by degree of browning (g/day)
Table 1: Baseline characteristics of cases and controls in the EPIC-Heidelberg nested case-control study on PCa 
(n=563).
Medium/ dark 10.7 (2.5-28.3) 13.3 (1.4-33.8)
Calcium (g/d) 0.8 (0.5-0.9) 0.8 (0.6-1.0)
Tomatoes, tomato products (g/d) 2.0 (1.0-3.0) 2.0 (1.0-3.0)
Red meat (g/d) 31.3 (20.7-50.0) 34.2 (19.7-58.6)
Processed meat (g/d) 51.9 (32.4-71.2) 56.3 (32.4-82.5)
White meat (g/d) 8.3 (4.3-15.5) 9.6 (3.9-17.2)
Alcohol (g/d)  21.8 (9.4-39.3) 18.4 (6.6-34.9)
Genotype All Cases (%) Controls (%)
GSTM1 
del/del 293 (52.04) 105 (51.72) 188 (52.22)
pres/del 220 (39.08) 81 (39.90) 139 (38.61)
pres/pres 50 (8.88) 17 (8.37) 33 (9.17)
HWE§ 0.35 0.32
GSTT1
del/del 99 (17.58) 35 (17.24) 64 (17.78)
pres/del 285 (50.62) 100 (49.26) 185 (51.39)
pres/pres 179 (31.79) 68 (33.50) 111 (30.83)
HWE§ 0.43 0.37
CC 382 (67.85) 132 (65.02) 250 (69.44)
CT 158 (28.06) 66 (32.51) 92 (25.56)
TT 23 (4.09) 5 (2.46) 18 (5.00)
HWE§ 0.2 0.02
GG 166 (29.48) 62 (30.54) 104 (28.89)
GA 278 (49.38) 100 (49.26) 178 (49.44)
AA 119 (21.14) 41 (20.20) 78 (21.67)
HWE§ 0.9 0.91
AA 258 (45.83) 100 (49.26) 158 (43.89)
AG 249 (44.23) 81 (39.90) 168 (46.67)
GG 56 (9.95) 22 (10.84) 34 (9.44)
HWE§ 0.72 0.26
CC 471 (83.66) 299 (83.06) 172 (84.73)
CT 91 (16.16) 61 (16.94) 30 (14.78)
TT 1 (0.18) 0 (0.00) 1 (0.49)
HWE§ 0.11 0.8
CC 143 (25.40) 53 (26.11) 90 (25.00)
CT 290 (51.51) 100 (49.26) 190 (52.78)
TT 130 (23.90) 50 (24.63) 80 (22.22)
HWE§ 0.47 0.28
CC 512 (90.94) 177 (87.19) 335 (93.06)
CA 51 (9.06) 26 (12.81) 25 (6.94)
HWE§ 0.26 0.49
TT 470 (83.47) 165 (81.28) 305 (84.72)
TC 89 (15.81) 35 (17.24) 54 (15.00)
CC 4 (0.71) 3 (1.48) 1 (0.28)
HWE§ 0.92 0.37
CYP1A1  *2A  (rs4646903)
GPX1  (rs1050450)
Table 2: Allele frequencies of selected genetic variants in PCa cases and controls 
in the EPIC-Heidelberg nested case-control study (n=563). 
NQO1  (rs1800566)
GSTA1  (rs3957357)
GSTP1  (rs1695) 
GSTP1  (rs1138272)
MnSOD  (rs4880)
CYP1A1*4   (rs1799814)
CC 302 (54.22) 104 (51.49) 198 (55.77)
CT 204 (36.62) 82 (40.59) 122 (34.37)
TT 51 (9.16) 16 (7.92) 35 (9.86)
HWE§ 0.74 0.02
CC 171 (30.54) 64 (31.84) 107 (29.81)
CT 266 (47.50) 91 (45.27) 175 (48.75)
TT 123 (21.96) 46 (22.89) 77 (21.45)
HWE§ 0.31 0.73
Abbreviations: HWE, Hardy-Weinberg equilibrium; 
§ P-value of χ2 test.
GPX4  C718T (rs713041)
Genotype Cases/Cont
rols
OR1 (95%CI) Pi OR1 (95%CI) Pi OR1 (95%CI) Pi
GSTM1 
pres/pres 17/33 0.71 (0.22-2.33) 0.96 (0.52-1.79) 1.01 (0.75-1.36)
pres/del 81/139 0.70 (0.49-1.00) 0.85 (0.68-1.07) 0.93 (0.79-1.08)
del/del 105/188 0.95 (0.82-1.09) 0.1 1.05 (0.97-1.16) 0.12 1.00 (0.93-1.07) 0.54
≥1 del 186/327 0.89 (0.77-1.02) 0.57 1.01 (0.93-1.10) 0.7 0.99 (0.93-1.0.5) 0.96
GSTT1
pres/pres 68/111 0.70 (0.49-0.99) 0.78 (0.60-1.01) 0.79 (0.63-0.98)
pres/del 100/185 0.99 (0.83-1.20) 1.09 (0.98-1.20) 1.01 (0.93-1.09)
del/del 35/64 0.88 (0.64-1.21) 0.38 0.96 (0.73-1.27) 0.18 1.00 (0.83-1.21) 0.11
≥1 del 135/249 0.95 (0.82-1.11) 0.14 1.07 (0.97-1.17) 0.05 1.01 (0.95-1.08) 0.05
0 or 1 del 44/69 0.55 (0.30-1.02) 0.73 (0.50-1.05) 0.69 (0.49-0.98)
2 del 73/141 0.76 (0.55-1.07) 0.85 (0.66-1.10) 0.95 (0.87-1.04)
3 or 4 del 86/150 1.01 (0.86-1.19) 0.03 1.09 (0.98-1.21) 0.01 1.02 (0.95-1.10) 0.03
CC 132/250 0.95 (0.82-1.10) 1.00 (0.88-1.13) 1.01 (0.92-1.11)
CT 66/92 0.74 (0.54-1.02) 1.03 (0.92-1.16) 0.58 (0.24-1.44)
TT Mai 18 1.16 (0.14-9.40) 0.16 0.54 (0.12-2.51) 0.88 NA 0.33
≥1 T 71/110 0.74 (0.54-1.01) 0.16 1.03 (0.92-1.15) 0.88 0.94 (0.86-1.03) 0.4
GG 62/104 0.77 (0.56-1.07) 1.02 (0.90-1.15) 0.99 (0.90-1.11)
GA 100/178 0.92 (0.76-1.11) 1.00 (0.86-1.15) 0.99 (0.89-1.10)
AA 41/78 0.87 (0.65-1.18) 0.66 0.93 (0.74-1.16) 0.58 0.91 (0.78-1.06) 0.38
≥1 A 141/256 0.90 (0.77-1.06) 0.5 0.98 (0.87-1.10) 0.6 0.96 (0.89-1.04) 0.47
AA 100/158 0.90 (0.77-1.06) 1.02 (0.91-1.14) 1.04 (0.95-1.14)
AG 81/168 0.88 (0.66-1.17) 0.95 (0.78-1.15) 0.91 (0.79-1.05)
GG 22/34 0.77 (0.46-1.26) 0.76 1.02 (0.87-1.20) 0.87 0.94 (0.83-1.06) 0.23
≥1 G 103/202 0.85 (0.65-1.09) 0.79 1.00 (0.89-1.13) 0.82 0.93 (0.85-1.01) 0.1
CC 172/299 0.88 (0.76-1.02) 0.98 (0.89-1.09) 1.02 (0.95-1.10)
CT 30/61 0.87 (0.55-1.37) 0.96 1.10 (0.92-1.32) 0.37 0.89 (0.77-1.03) 0.17
TT 0/0 NA NA NA
CC 53/90 0.77 (0.54-1.10) 1.10 (0.96-1.26) 1.12 (0.97-1.29)
CT 100/190 0.93 (0.79-1.09) 0.97 (0.85-1.11) 1.04 (0.94-1.14)
TT 50/80 0.83 (0.58-1.19) 0.72 0.93 (0.73-1.20) 0.2 0.83 (0.66-1.04) 0.02
≥1 T 150/270 0.91 (0.78-1.06) 0.42 0.96 (0.86-1.08) 0.19 0.96 (0.90-1.03) 0.08
CC 177/335 0.86 (0.74-1.01) 0.97 (0.87-1.08) 1.01 (0.94-1.09)
CA 26/25 0.99 (0.68-1.46) 0.62 1.11 (0.90-1.37) 0.26 0.95 (084-1.07) 0.29
Table 3: Relative risk (OR, 95%CI) of PCa with increasing energy-adjusted HCA intake (ng/1000kcal) in 
strata of selected genotypes in the EPIC-Heidelberg nested case-control study on PCa (n=563). 
GSTP1  (rs1695) 
GSTP1  (rs1138272)
MnSOD  (rs4880)
CYP1A1  (rs1799814)
CYP1A1  (rs4646903)
50 ng/day increments of energy-
adjusted PhIP intake
10 ng/day increments of 
energy-adjusted MeIQx intake
1 ng/day increments of energy-
adjusted DiMeIQx intake
GSTT1/GSTM1
NQO1  (rs1800566)
GSTA1  (rs3957357)
TT 165/305 0.88 (0.77-1.02) 1.02 (0.94-1.11) 1.00 (0.94-1.06)
TC 35/54 1.00 (0.59-1.71) 0.88 (0.60-1.29) 0.94 (0.73-1.20)
CC 03. Jan NA 0.75 NA 0.4 NA 0.46
≥1 C 38/55 0.99 (0.58-1.68) 0.72 0.88 (0.60-1.30) 0.39 0.93 (0.73-1.19) 0.48
CC 104/198 0.86 (0.71-1.04) 1.04 (0.94-1.15) 0.97 (0.89-1.05)
CT 82/122 0.80 (0.59-1.09) 0.88 (0.72-1.07) 1.01 (0.92-1.11)
TT 16/35 2.17 (1.00-4.61) 0.17 1.27 (0.93-1.74) 0.87 1.03 (0.80-1.33) 0.55
≥1 T 98/157 0.93 (0.76-1.13) 0.65 0.97 (0.84-1.13) 0.37 1.01 (0.93-1.11) 0.51
CC 64/107 0.77 (0.55-1.09) 1.03 (0.93-1.15) 1.10 (0.99-1.22)
CT 91/175 0.89 (0.75-1.05) 1.00 (0.86-1.15) 0.93 (0.82-1.07)
TT 46/77 0.99 (0.70-1.41) 0.29 0.98 (0.72-1.31) 0.64 0.90 (0.77-1.04) 0.03
≥1 T 137/252 0.90 (0.78-1.04) 0.39 0.99 (0.87-1.12) 0.66 0.92 (0.83-1.01) 0.01
Abbreviation: Pi, P-value for test of interaction between HCA intake and genotype; NA, not available.
GPX4  C718T (rs713041)
1: OR calculated by unconditional logistic regression adjusted for matching variables (time of recruitment ad 5-year age group) and family 
history of prostate cancer.
GPX1  (rs1050450)
Genotype Cases/Controls OR1 (95%CI) Pi OR1 (95%CI) Pi
GSTM1 
pres/pres 17/33 0.85 (0.62-1.16) 0.92 (0.74-1.16)
pres/del 81/139 1.01 (0.91-1.13) 0.97 (0.88-1.07)
del/del 105/188 0.95 (0.87-1.04) 0.97 0.94 (0.85-1.04) 0.63
≥1 del 186/327 0.98 (0.91-1.04) 0.23 0.96 (0.89-1.02) 0.85
GSTT1
pres/pres 68/111 0.86 (0.75-0.98) 0.90 (0.81-1.01)
pres/del 100/185 1.03 (0.94-1.12) 0.95 (0.86-1.06)
del/del 35/64 0.92 (0.76-1.11) 0.25 1.08 (0.93-1.25) 0.1
≥1 del 135/249 1.01 (0.94-1.09) 0.07 0.99 (0.91-1.08) 0.19
GSTT1/GSTM1
0 or 1 del 44/69 0.88 (0.74-1.04) 0.87 (0.75-1.00)
2 del 73/141 0.97 (0.86-1.08) 1.01 (0.92-1.12)
3 or 4 del 86/150 0.99 (0.90-1.09) 0.24 0.96 (0.86-1.08) 0.43
CC 132/250 0.99 (0.90-1.08) 0.97 (0.90-1.05)
CT 66/92 0.95 (0.85-1.06) 0.91 (0.80-1.04)
TT Mai 18 0.73 (0.43-1.24) 0.18 1.11 (0.77-1.60) 0.74
≥1 T 71/110 0.93 (0.84-1.03) 0.33 0.92 (0.82-1.04) 0.59
GG 62/104 0.94 (0.82-1.08) 0.88 (0.75-1.03)
GA 100/178 0.98 (0.89-1.07) 0.96 (0.89-1.04)
AA 41/78 0.98 (0.86-1.13) 0.49 1.05 (0.90-1.23) 0.12
≥1 A 141/256 0.98 (0.91-1.06) 0.54 0.98 (0.91-1.05) 0.17
AA 100/158 0.98 (0.90-1.07) 0.95 (0.87-1.04)
AG 81/168 0.98 (0.88-1.08) 0.92 (0.82-1.03)
GG 22/34 0.82 (0.62-1.08) 0.3 1.14 (0.89-1.45) 0.54
≥1 G 103/202 0.95 (0.86-1.05) 0.53 0.95 (0.86-1.05) 0.9
CC 172/299 0.98 (0.91-1.05) 0.95 (0.88-1.02)
CT 30/61 0.89 (0.72-1.09) 0.31 1.01 (0.87-1.18) 0.38
TT 0/0 NA NA
CC 53/90 1.03 (0.91-1.16) 1.08 (0.95-1.23)
CT 100/190 1.02 (0.93-1.12) 0.83 (0.74-0.92)
TT 50/80 0.74 (0.60-0.91) 0.02 1.13 (0.98-1.30) 0.81
≥1 T 150/270 0.95 (0.87-1.03) 0.33 0.92 (0.85-0.99) 0.04
CC 177/335 0.94 (0.87-1.01) 0.96 (0.89-1.03)
CA 26/25 1.06 (0.90-1.24) 0.11 0.92 (0.74-1.16) 0.88
TT 165/305 0.99 (0.92-1.06) 0.97 (0.90-1.04)
Table 4: Relative risk (OR, 95%CI) of PCa with increasing meat intake by degree of 
browning in strata of selected genotypes in the EPIC-Heidelberg nested case-control 
study on PCa (n=563). 
CYP1A1  (rs1799814)
CYP1A1  (rs4646903)
MnSOD  (rs4880)
GSTP1  (rs1695) 
GSTP1  (rs1138272)
GSTA1  (rs3957357)
NQO1  (rs1800566)
10g/day increments of meat 
consumed dark
10g/day increments of meat 
consumed light
TC 35/54 0.82 (0.64-1.06) 0.87 (0.70-1.09)
CC NA 0.21 NA 0.42
≥1 C 38/55 0.84 (0.66-1.06) 0.16 0.88 (0.71-1.08) 0.49
CC 104/198 0.94 (0.85-1.03) 0.93 (0.85-1.02)
CT 82/122 0.99 (0.90-1.09) 1.01 (0.91-1.11)
TT 1.06 (0.79-1.42) 0.31 0.89 (0.66-1.20) 0.52
≥1 T 98/157 1.00 (0.91-1.10) 0.46 0.99 (0.91-1.09) 0.26
CC 64/107 0.95 (0.84-1.08) 0.99 (0.89-1.09)
CT 91/175 1.00 (0.91-1.09) 0.96 (0.87-1.06)
TT 46/77 0.89 (0.76-1.04) 0.67 0.88 (0.74-1.05) 0.27
≥1 T 137/252 0.97 (0.89-1.09) 0.99 0.94 (0.86-1.02) 0.55
Abbreviation: Pi, P-value for test of interaction between HCA intake and genotype; NA, not available.
1: OR calculated by unconditional logistic regression adjusted for matching variables (time of recruitment ad 5-year age 
group), family history of prostate cancer, and energy-intake (kJ/d).
GPX4  C718T (rs713041)
GPX1  (rs1050450)
